Janet Campbell is Chairman and CEO of Dominion Aesthetic Technologies, Inc. Dominion is pioneering the development and commercialization of a first-in-class platform for non–invasive aesthetic procedures. The target market is focused on the fastest growing aesthetic applications. She has assembled a team comprised of some of the world’s leading laser experts who have developed and commercialized over 75 lasers for an array of industries including the aesthetic market. The aesthetic system is currently in development.
Ms. Campbell is the founder and former Chairman and CEO of Seno Medical Instruments, Inc., based in San Antonio.
Seno is the world’s leader in the research, development, and commercialization of opto-acoustics for cancer diagnosis. This technology is the first new functional imaging technology developed in 20 years. Ms. Campbell secured over $100M in investment capital for Seno. As CEO, she oversaw the FDA PMA (pre-market approval) which included the largest diagnostic study conducted in the U.S. She secured the CE Mark Approval for European sales. Prestigious institutions that participated in Seno’s U.S. study included MD Anderson, Cleveland Clinic, Yale, Northwestern, Georgetown and New York Weill Cornell. Under her leadership, Seno received numerous local and national recognitions such as the Stars of Satai and the Frost & Sullivan Awards.
Previously, Ms. Campbell served as President and Chief Operating Officer of InforMedix, Inc., where she commercialized technology and took the company public. She was Chief Executive Officer of Mach Diagnostics, a venture capital based medical company focused on rapid diagnostics for women’s healthcare. She founded Health Tech, Inc., a management and consulting firm in the medical field. There she used her international managerial experience to assist firms strategically in finance and business. Her knowledge of medical products and market changes positioned her with solid working relationships for emerging and Fortune 500 companies and venture capital communities, such as the Woodlands Venture Fund (The Essex Woodlands), Vanguard Ventures and the Susquehanna Group. Ms. Campbell also was the healthcare partner of Rockecharlie & Co., a Houston-based investment banking firm.
She is a board member of the Texas Business Hall of Fame. Previously, Human Genome Science appointed her as their board representative to Vascular Genetics Inc., where she was elected Chairman of the Board. While residing in Maryland, she was on the Board of Directors of the High Tech Council of Maryland Incubator. She is a founding member of the Board of Directors of the Bioscience Committee and the Jewish Federation in Washington, D.C. Ms. Campbell was a board member of the Griffith’s Leadership Society for Women at the University of Missouri and served as a special volunteer and guest researcher for the Office of Technology Transfer for the National Institutes of Health. She previously served as an independent reviewer for NIH grants in the cardiovascular arena.
Ms. Campbell was recognized by the University of Missouri as Alumni of the Year in 2005 from the School of Arts and Science. She was the recipient of the international Gold Stevie Award for Female Entrepreneur of the Year in 2013. The San Antonio Business Journal honored her as CEO of the year in the field of medical devices. She was also featured as one of only three CEO’s in The Texas CEO Magazine. She was inducted into the San Antonio Women’s Hall of Fame in 2016.
Ms. Campbell received her BA from the University of Missouri, Columbia and her MBA in finance from Johns Hopkins University. She is a member of the Cosmos Club in Washington D.C.